93 results
Page 2 of 5
8-K
EX-99.2
w5k6so4quhm
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.1
sq88b7 p8h
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.1
ha4zj
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.2
tntvhcv
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
bpwneec
16 Mar 21
Aravive Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates
7:15am
8-K
EX-99.1
v150ojl0
8 Mar 21
Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma
7:05am
424B5
zqvvydl1 cui9
16 Feb 21
Prospectus supplement for primary offering
7:05am
8-K
EX-99.1
h7ht7xxb loj
4 Jan 21
Aravive Announces Board Member Transition to Advisory Role
4:11pm
8-K
EX-99.1
p2lzzj367pjx inqc2lw
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.2
7aqy kb84u7rtwdayxb9
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
89h w0ofjunwlgh4s0a5
5 Nov 20
Aravive Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
4:31pm
8-K
EX-99.1
zm1lz7lxn kvg
8 Oct 20
Regulation FD Disclosure
5:01pm
8-K
EX-99.1
yg4 taohs3e5pw7prf
3 Aug 20
Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates
4:10pm
8-K
EX-99.1
bsrk4rmeprm172zkc
23 Jul 20
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
7:05am
8-K
EX-99.2
34fvs3unl1a9
23 Jul 20
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
7:05am